Printer Friendly

T CELL SCIENCES AND AB ASTRA EXPAND AGREEMENT TO DEVELOP THERAPEUTIC PRODUCTS

 CAMBRIDGE, Mass., Dec. 14 /PRNewswire/ -- T Cell Sciences, Inc., (NASDAQ: TCEL), today announced the signing of an amended and restated product development and distribution agreement with AB Astra covering products resulting from T Cell Sciences' proprietary T cell receptor (TCAR) technology. The original agreement signed in January 1992 called for funding of approximately $15 million to be received by T Cell Sciences in the initial years of the program and the potential of further investment by Astra of up to $17 million, pursuant to options and based on milestones, in future years.
 In order to meet the objectives as outlined in the original agreement, T Cell Sciences and Astra have signed an amended agreement, in which Astra has reaffirmed its original funding and has agreed to increase its commitment to the program by assuming responsibility from T Cell Sciences for future development and manufacturing of the two monoclonal antibody candidates, TM27 and TM29. The percentage of net sales to be paid to T Cell Sciences by Astra has been adjusted to reflect Astra's substantial additional development and manufacturing commitment.
 "In the last eighteen months the joint program has accomplished the goals of humanizing two monoclonal antibody product candidates and producing a peptide candidate," said Alan W. Tuck, president and chief executive officer of T Cell Sciences. "The amended agreement makes better use of each company's resources which will be directed toward the jointly agreed upon commercialization strategy for these initial three agents and future TCAR therapeutics."
 T Cell Sciences, with funding support from Astra, is responsible for the development and manufacturing of the initial peptide candidate, TP12. Astra retains worldwide marketing rights to all products derived from the TCAR technology, with the exception of rheumatoid arthritis products in North America, and now will share manufacturing responsibility for future agents with T Cell Sciences.
 T Cell Sciences and Astra also have entered into an agreement whereby Astra will fund expansion of research space, dedicated to TCAR product development, at T Cell Sciences. "This increased support emphasizes the need for an active research program which will foster additional product candidates," said Alan Tuck. "The additional research space also provides labs for T Cell Sciences' scientists and Astra scientists to work as a team, both having an active role in the research and product development process."
 The product candidates being developed by T Cell Sciences and Astra are targeted to the specific subpopulations of T cells which are believed to be key in the progression of autoimmune diseases. The initial two product candidates are humanized monoclonal antibodies, TM27 and TM29. TM27 and TM29 are being developed as treatments for multiple sclerosis and Crohn's disease, respectively. The third product candidate is a peptide, TP12, targeted to certain T cells thought to be implicated in multiple sclerosis.
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and complement receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, a wholly-owned subsidiary of T Cell Sciences, develops, manufactures and markets innovative diagnostic and research products.
 -0- 12/14/93
 /CONTACT: Alan W. Tuck, president and chief executive officer or Susan Primrose, manager, market development and communications, of T Cell Sciences, 617-621-1400/
 (TCEL)


CO: T Cell Sciences, Inc.; AB Astra ST: Massachusetts IN: MTC SU:

DJ-RP -- NE001 -- 3479 12/14/93 08:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 14, 1993
Words:558
Previous Article:INTERNATIONAL TECHNOLOGY CORP. AWARDED NATIONWIDE AIR FORCE CENTER FOR ENVIRONMENTAL EXCELLENCE ARCHITECTURAL AND ENGINEERING SERVICE CONTRACT
Next Article:BELIZE HOLDINGS INC. REPORTS HALF-YEAR EARNINGS INCREASE OF 20 PERCENT; BANKING AND FINANCIAL SERVICES POST STRONG PERFORMANCE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters